Biotech Drug Report Generated Jul 3, 2026

sabizabulin

VERU·VERU INC.

BEARISH

Drug Impact Rating2/10

Trial Phase: Phase 3 (terminated)
Time to Market: Unknown — the drug is effectively sidelined with no active registrational trials. Repositioning for atherosclerosis is at early/preclinical stage with no Phase 2 enrollment started. No path to market visible within 5+ years if at all.
Why 2/10: Sabizabulin has no scheduled hard, dated catalyst in the next ~12 months. The Phase 3 VERACITY prostate cancer trial was terminated, the COVID-19 EUA was rejected, and the drug has been sidelined due to funding while Veru pivots to its lead asset enobosarm. The proposed atherosclerosis program is at a preclinical/Phase 2 planning stage with no trial enrollment initiated.

Actionable Insight BEARISH

Sabizabulin is no longer a meaningful near-term value driver for VERU. The company's valuation now rests almost entirely on the enobosarm program (Phase 2b PLATEAU trial in obesity, interim data expected Q1 2027). Investors should not trade VERU based on sabizabulin expectations.

Price Chart

Loading chart...

Executive Summary

Sabizabulin is an oral tubulin inhibitor that Veru Inc. originally developed for prostate cancer and then pivoted to COVID-19. After showing a striking 55% mortality reduction in a Phase 3 COVID trial, an FDA advisory committee voted 8-5 against emergency authorization in Nov 2022, effectively killing that program. The prostate cancer Phase 3 (VERACITY) was subsequently terminated. As of mid-2026, Veru has largely shelved sabizabulin, pivoted to cardiometabolic diseases, and is now exploring the drug as a preclinical anti-inflammatory agent for atherosclerosis. The company's valuation is now driven entirely by enobosarm. Sabizabulin has no near-term catalysts and is not investable as a standalone thesis.

How It Works

Sabizabulin is an oral small molecule that disrupts microtubules — the tiny structural "highways" inside cells that transport materials. By gumming up these highways, it can kill rapidly dividing cells (cancer), block viruses from hijacking cells (COVID-19), and tamp down inflammation. It works differently from standard chemo drugs like taxanes.

Trial Status

The Phase 3 VERACITY trial (NCT04844749) for metastatic castration-resistant prostate cancer was terminated in early 2024 for administrative reasons. The COVID-19 program failed to secure FDA EUA after an 8-5 advisory committee vote against it in Nov 2022, and a planned confirmatory Phase 3 never materialized. The drug is now being explored preclinically for atherosclerosis, with a Phase 2 study proposed but not yet enrolling.

The Two-Sided Case

▲ Bull Case5

Phase 3 COVID data showed a 55% relative reduction in all-cause mortality — a clinically meaningful signal that could support eventual approval if funding is found for a confirmatory trial.

Sabizabulin's dual anti-viral and anti-inflammatory mechanism is mechanistically distinct, potentially giving it utility beyond COVID in inflammatory conditions like atherosclerosis.

Oral administration is a significant convenience advantage over injectable anti-inflammatory biologics, potentially supporting broad use if developed successfully for atherosclerosis.

The drug already has Fast Track designation from the FDA (granted Jan 2022), which could accelerate regulatory reviews if development resumes.

Veru's pipeline page still lists sabizabulin as a second late-stage NCE, suggesting the company has not completely abandoned the asset.

▼ Bear Case6

The COVID-19 EUA was rejected by an 8-5 FDA advisory committee vote in Nov 2022, and the confirmatory Phase 3 trial Veru agreed to with the FDA was never initiated — the program is effectively dead.

The Phase 3 VERACITY trial in prostate cancer (NCT04844749) was terminated in Feb 2024 for administrative reasons with no results reported.

Analyst commentary describes sabizabulin as 'sidelined due to funding' — Veru's cash position ($27.6M as of Mar 2026) is being directed to the enobosarm program, not sabizabulin.

The proposed atherosclerosis indication is at an early/preclinical stage with no Phase 2 trial enrollment even initiated — years away from any catalyst.

Veru's entire valuation is now tethered to enobosarm, making sabizabulin at best a long-dated pipeline option with no near-term value.

The drug has no approvals anywhere in the world as of mid-2026.

Upcoming Catalysts

No hard catalysts scheduled for sabizabulin in the next 12 months.
Veru's enobosarm Phase 2b PLATEAU trial (obesity + GLP-1) interim analysis expected Q1 2027 — this is the company's real catalyst, not sabizabulin.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

VERU INC. 8-K VERU ·Originating report

Sources · 11

Hover a chip for the title

1 en.wikipedia.org2 clinicaltrials.gov3 healio.com4 ir.verupharma.com5 verupharma.com6 verupharma.com7 ir.verupharma.com8 sahmcapital.com9 fda.gov10 empr.com11 finsee.ai